{"id":517548,"date":"2021-07-26T09:42:07","date_gmt":"2021-07-26T13:42:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shingrix-approved-in-the-us-for-prevention-of-shingles-in-immunocompromised-adults\/"},"modified":"2021-07-26T09:42:07","modified_gmt":"2021-07-26T13:42:07","slug":"shingrix-approved-in-the-us-for-prevention-of-shingles-in-immunocompromised-adults","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shingrix-approved-in-the-us-for-prevention-of-shingles-in-immunocompromised-adults\/","title":{"rendered":"Shingrix approved in the US for prevention of shingles in immunocompromised adults"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n LONDON<\/span> and PHILADELPHIA<\/span>, July 26, 2021<\/span> \/PRNewswire\/ — GlaxoSmithKline plc today announced that the US Food and Drug Administration (FDA) has approved Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in adults aged 18 years and older who are or who will be at increased risk of shingles due to immunodeficiency or immunosuppression caused by known disease or therapy. Immunocompromised individuals are at greater risk of shingles and associated complications than immunocompetent individuals.<\/p>\n

\n

\n
\n \"(PRNewsfoto\/GlaxoSmithKline
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Shingrix, a non-live, recombinant sub-unit adjuvanted vaccine, given intramuscularly in two doses, was initially approved by FDA in 2017 for the prevention of shingles in adults 50 years of age or older. Shingrix is not indicated for prevention of primary varicella infection (chickenpox).\u00a0The approval for this new population expands the number of people who can be protected against shingles by Shingrix.<\/p>\n

“We’re proud to offer Shingrix in the US for the prevention of shingles in those who are immunocompromised, with FDA granting a broad indication for use in adults at increased risk of this disease,” said Thomas Breuer<\/span>, Chief Medical Officer, GSK Vaccines. “Older age and being immunocompromised are the most common risk factors for shingles disease. GSK is committed to this important patient population at increased risk for shingles disease and its complications by bringing them a vaccine option that can help prevent this painful condition.”<\/p>\n

The GSK Clinical Development Program evaluated the benefit-risk profile of Shingrix in heterogeneous immunocompromised patient populations.<\/p>\n

This approval for a new population was based on clinical studies examining the safety and efficacy of Shingrix in adults (\u226518 years of age) who had undergone an autologous hematopoietic stem cell transplant (auHSCT) and those undergoing treatment for hematological malignancies (post-hoc analysis). Further safety and immunogenicity data were generated in adults who were, or were anticipated to be, immunodeficient or immunosuppressed due to known disease or therapy, including patients with HIV, solid tumors, and renal transplants.1,2,3,4,5,6\u00a0<\/sup><\/p>\n

“In addition to this new patient population, there are more than 100 million adults 50 years and older in the US already recommended to receive Shingrix,” said Breuer. “We know many of these individuals missed recommended vaccines during the pandemic and we hope this can be a reminder to them to catch up on all their immunizations, including Shingrix.”<\/p>\n

According to recently published report<\/a>\u00a0from Avalere Health and supported by GSK, more than 17 million doses of recommended vaccines, including Shingrix, were missed by adults during the pandemic.<\/p>\n

Shingrix is the first shingles vaccine indicated for use in those who are at increased risk of the disease due to being immunodeficient or immunosuppressed due to disease or therapy. It combines a non-live antigen, to trigger a targeted immune response, with a specifically designed adjuvant system to generate a Varicella Zoster Virus (VZV)-specific immune response.\u00a0For immunocompetent adults, Shingrix is intended to be administered in two doses, 2 to 6 months apart.<\/p>\n

However, for adults who are or will be immunodeficient or immunosuppressed due to known disease or therapy and who would benefit from a shorter vaccination schedule, the second dose can be administered 1 to 2 months after the first dose.<\/p>\n

The US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) has begun discussions to consider recommendations for use of Shingrix in immunocompromised adults.<\/p>\n

Shingrix was previously approved by the European Commission (EC) for prevention of shingles and post-herpetic neuralgia (PHN) in adults 18 years of age or older at increased risk of shingles and granted marketing authorization on August 25, 2020<\/span>.<\/p>\n

\n About Shingles
<\/b>Shingles is caused by the reactivation of the varicella zoster virus (VZV), the same virus that causes chickenpox.7<\/sup>\u00a0Nearly all older adults have the VZV dormant in their nervous system, waiting to reactivate with advancing age.8<\/sup>\u00a0As people age, the cells in the immune system lose the ability to maintain a strong and effective response to VZV reactivation.7,9<\/sup>\u00a0<\/p>\n

Shingles typically presents as a painful, itchy rash that develops on one side of the body and can last for two to four weeks.9,10<\/sup>\u00a0The pain associated with shingles is often described as burning, shooting or stabbing.\u00a0Even once the rash is gone, a person can experience postherpetic neuralgia (PHN), pain lasting from at least three months up to several years.7<\/sup>\u00a0PHN is the most common complication of shingles, occurring in 10 to 18 percent of all shingles cases.7,11<\/sup><\/p>\n

There are an estimated 1 million cases of shingles in the US each year.7<\/sup>\u00a0\u00a0More than 99 percent of those over 50 years old are infected with VZV, and one in three Americans will develop shingles in their lifetime. The risk increases to one in two for adults aged 85 years and older.\u00a0<\/p>\n

\n About Shingrix
<\/b>Shingrix is a non-live, recombinant subunit vaccine approved in the US, Canada<\/span>, EU, UK, China<\/span>, Japan<\/span>, Hong Kong<\/span>, Australia<\/span>, New Zealand<\/span>, and Singapore<\/span> to help prevent shingles (herpes zoster) in people aged 50 years or older. It combines an antigen, glycoprotein E, and an adjuvant system, AS01B<\/sub>, intended to generate a Varicella Zoster Virus (VZV)-specific immune response immune response that can help overcome the decline in immunity as people age.<\/p>\n

Shingrix was previously approved by the European Commission (EC) and in the UK for prevention of shingles and post-herpetic neuralgia (PHN) in adults 18 years of age or older at increased risk of shingles and granted marketing authorization on August 25, 2020<\/span>.<\/p>\n

The updated US Prescribing Information will be available soon at www.gskpro.com<\/a>. <\/p>\n

\n Important Safety Information for Shingrix
<\/b>The following is based on the US Prescribing Information for Shingrix. Please consult the full Prescribing information for all the labeled safety information.<\/p>\n